Ejaculation disorder is associated with increased efficacy of silodosin for benign prostatic hyperplasia

Urology

Volumn 76, Issue 6, 2010, Pages 1446-1450

  Homma, Yukio ^a,b,c,d   Kawabe, Kazuki ^a,b,c,d   Takeda, Masayuki ^a,b,c,d   Yoshida, Masaki ^a,b,c,d  

^a UNIVERSITY OF TOKYO   (Japan)

^b TOKYO TEISHIN HOSPITAL   (Japan)

^c UNIVERSITY OF YAMANASHI   (Japan)

^d KUMAMOTO ROSAI HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1A ADRENERGIC RECEPTOR; PLACEBO; SILODOSIN; TAMSULOSIN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EJACULATION DISORDER; HUMAN; INTERNATIONAL PROSTATE SYMPTOM SCORE; JAPAN; MAJOR CLINICAL STUDY; MALE; PHASE 3 CLINICAL TRIAL; POST HOC ANALYSIS; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL;

ADRENERGIC ALPHA-ANTAGONISTS; AGED; DOUBLE-BLIND METHOD; EJACULATION; HUMANS; INDOLES; MALE; MIDDLE AGED; PATIENT ACCEPTANCE OF HEALTH CARE; PATIENT DROPOUTS; PROSTATIC HYPERPLASIA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEVERITY OF ILLNESS INDEX; SULFONAMIDES;

EID: 78649920033     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2010.03.015     Document Type: Article

References (28)

1. H. Lepor Pathophysiology of lower urinary tract symptoms in the aging male population Rev Urol 7 2005 S3 S11
2. H. Lepor Alpha blockers for the treatment of benign prostatic hyperplasia Rev Urol 9 2007 181 190
3. 1-adrenoceptor subtypes and lower urinary tract symptoms Int J Urol 15 2008 193 199
4. K. Shibata, R. Foglar, and K. Horie KMD-3213, a novel, potent, α 1a-adrenoceptor-selective antagonist: characterization using recombinant human α 1-adrenoceptors and native tissues Mol Pharmacol 48 1995 250 258
5. 1-adrenoceptor antagonist, in human prostate and vasculature J Urol 164 2000 578 583
6. 1A-adrenoceptor subtype selectivity of KMD-3213 in rat tissues J Pharmacol Exp Ther 296 2001 160 167
7. 1A-adrenoceptor antagonist, on the prostatic urethral pressure and blood pressure in male decerebrate dogs Int J Urol 8 2001 177 183
8. 1a-adrenoceptor-selective antagonist, on the contractions of rabbit prostate and rabbit and rat aorta Eur J Pharmacol 315 1996 73 79
9. 1A-adrenoceptor-selective antagonist for treating benign prostatic hyperplasia: results of a phase 3 randomized, placebo-controlled, double-blind study in Japanese men BJU Int 98 2006 1019 1024
10. 1A-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies J Urol 181 2009 2634 2640
11. 1a-adrenoceptor subtype in the rat, monkey and human urinary bladder and prostate J Urol 157 1997 1032 1038
12. X.L. Rudner, D.E. Berkowitz, and J.V. Booth Subtype specific regulation of human vascular alpha (1)-adrenergic receptors by vessel bed and age Circulation 100 1999 2336 2343
13. A. Hatano, H. Takahashi, and M. Tamaki Pharmacological evidence of distinct alpha 1-adrenoceptor subtypes mediating the contraction of human prostatic urethra and peripheral artery Br J Pharmacol 113 1994 723 728
14. 1-Adrenergic Receptors and Their Inhibitors in Lower Urinary Tract Symptoms and Benign Prostatic Hyperplasia J Urol 171 2004 1029 1035
15. 1-adrenergic receptor subtypes in lower urinary tract symptoms BJU Int 88 2001 27 34
16. 1-adrenergic receptor that mediates smooth muscle contraction in human prostate has the pharmacological properties of the cloned human α1C-subtype Mol Pharmacol 45 1994 703 708
17. C. Chapple, and K.E. Andersson Tamsulosin: an overview World J Urol 19 2002 397 404
18. 1- adrenoceptor antagonists in the lower urinary tract and central nervous system Nat Clin Pract Urol 4 2007 368 378
19. M.A. Scofield, F. Liu, and P.W. Abel Quantification of steady state expression of mRNA for alpha-1 adrenergic receptor subtypes using reverse transcription and a competitive polymerase chain reaction J Pharmacol Exp Ther 275 1995 1035 1042
20. 1-adrenoceptors and ejaculatory function Br J Pharmacol 152 2007 289 290
21. G.M. Clifford, and R.D. Farmer Medical therapy for benign prostatic hyperplasia: a review of the literature Eur Urol 38 2000 2 19
22. K. Kobayashi, N. Masumori, and S. Hisasue Inhibition of seminal emission is the main cause of anejaculation induced by a new highly selective α1A-blocker in normal volunteers J Sex Med 5 2008 2185 2190
23. S. Hisasue, R. Furuya, and N. Itoh Ejaculatory disorder caused by alpha-1 adrenoceptor antagonists is not retrograte ejaculation but a loss of seminal emission Int J Urol 13 2006 1311 1316
24. Y. Homma, K. Kawabe, and T. Tsukamoto Estimate criteria for efficacy of treatment in benign prostatic hyperplasia Int J Urol 3 1996 267 273 (Pubitemid 26264298)
25. 1- blocker silodosin: A preliminary study to analyze human ejaculation using color Doppler ultrasonography Int J Urol 15 2008 915 918
26. Roehrborn CG. Silodosin in men with BPH-related symptoms: relationship between efficacy and drug-related retrograde ejaculation. Poster #44 At the 83rd Annual Meeting of the North Central Section of the American Urological Association, Scottsdale, Arizona, November 9-14, 2009.
27. 1-adrenoceptor antagonists on intraurethral pressure in the prostatic urethra and intraluminal pressure in the vas deferens in male dogs Eur J Pharmacol 580 2008 256 261
28. 1-adrenoceptors are required for normal male sexual function Br J Pharmacol 152 2007 332 340